Our Pipeline

These product candidates are designed to produce mixed chimerism, the coexistence of recipient and donor blood and immune cells in the recipient. For organ transplant patients, mixed chimerism can induce donor-specific immune tolerance, which reduces the likelihood of transplant organ loss, reduces or eliminates chronic immunosuppressive drug therapy, and thereby improves patient outcomes. For hematologic conditions, mixed chimerism has the potential to reduce or eliminate disease symptoms.

Medeor Therapeutics is the recipient of a grant by California Institute for Regenerative Medicine (CIRM) to support the ongoing Phase 3 study of MDR-101.